SOUTH SAN FRANCISCO, Calif.–(HSMN NewsFeed)–Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III study CRUISE showed Lucentis(R) (ranibizumab injection) improved vision, as measured by…
Biopharmaceuticals, Ophthalmology
Genentech, Lucentis, ranibizumab, macular edema, retinal vein occlusion

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion”
Leave a Comment